This week we have two fantastic interviews for you: The first is with Dr. Ben Mazer on the interplay between social media and news; the second is with Dr. Tem Bendapudi on whether Caplacizumab should be the standard of care for thrombotic thrombocytopenic purpura (TTP).

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

This week we have two fantastic interviews for you: The first is with Dr. Ben Mazer on the interplay between social media and news; the second is with Dr. Tem Bendapudi on whether Caplacizumab should be the standard of care for thrombotic thrombocytopenic purpura (TTP). Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.18 Social Media and News with Dr. Benjamin Mazer & Caplacizumab for TTP with Dr. Tem Bendapudi

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Medicine

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service. A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, &amp; health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Share 3.18 Social Media and News with Dr. Benjamin Mazer & Caplacizumab for TTP with Dr. Tem Bendapudi

Sign up to save your podcasts

3.18 Social Media and News with Dr. Benjamin Mazer & Caplacizumab for TTP with Dr. Tem Bendapudi

3.18 Social Media and News with Dr. Benjamin Mazer & Caplacizumab for TTP with Dr. Tem Bendapudi

More shows like Plenary Session - inactive due to federal service

EconTalk

Planet Money

This Week in Virology

Conversations with Tyler

JAMA Clinical Reviews

AFP: American Family Physician Podcast

White Coat Investor Podcast

JAMA Medical News

The Readout Loud

The Peter Attia Drive

All-In with Chamath, Jason, Sacks & Friedberg

Biotech Hangout

The VPZD Show

Two Onc Docs

Sensible Medicine